Dimple Patel recently joined the executive leadership team at VCU Massey Comprehensive Cancer Center, where she will serve as the associate director for innovation, leadership, and professional development. Patel brings 25 years of leadership experience spanning six public and private institutions of higher education.
Khalil Choucair has joined the thoracic oncology and phase I clinical trials multidisciplinary teams as a medical oncologist at Karamos Cancer Institute.
The National Academy of Inventors has elected the newest class of Fellows, naming 169 U.S. distinguished academic and institutional inventors and 16 International Fellows to the 2025 cohort.
Cynthia R. Moran, executive vice president of government relations, economics, and health policy at the American College of Radiology, will retire effective Jan. 2, 2026.
Patients with oropharyngeal cancers who were treated with proton therapy, compared to traditional radiation therapy saw a significant survival benefit, according to the findings from a phase III trial led by researchers at the University of Texas MD Anderson Cancer Center.
A guideline from the American Society of Clinical Oncology offers clear, evidence-based direction for treating blood cancers during pregnancy and shows that many patients can safely receive timely cancer care without compromising fetal health.
American Cancer Society scientists report higher cancer mortality rates among adults living in rural areas, certain congressional districts, and among those with lower socioeconomic status, according to a report published this month.
A study led by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute found the drug pirtobrutinib worked as well as another drug, ibrutinib, in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma, and people in the study responded better with pirtobrutinib.
Researchers presented updated data at ESMO IO from the phase III POD1UM-303/InterAACT 2 trial of retifanlimab-dlwr (Zynyz) in combination with platinum-based chemotherapy (carboplatin and paclitaxel) in adult patients with squamous cell carcinoma of the anal canal.
Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients with pancreatic neuroendocrine tumors need closer monitoring because their cancer is more likely to recur.
